FDA Releases New Opioid Plan as Senators Stall Robert Califf’s Confirmation as Commissioner

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Robert Califf, the nominee to serve as the next FDA commissioner, and other FDA leaders called for a broad plan to reassess the agency’s approach to prescription opioid medications. The move comes as Senators block a vote on his confirmation for the top post.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report. 
Conor Hale
Conor Hale

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login